Rifaximin DR is under clinical development by Alfasigma and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rifaximin DR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rifaximin DR overview
Rifaximin delayed-release formulation is under development for the treatment crohn's disease, sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs) and papulopustular rosacea. It is a small molecule which is administered through oral route. Rifaximin is gut selective antibiotic acts by targeting bacterial DNA-dependent RNA polymerase.
It was under development for the treatment of recurrent acute diverticulitis.
Alfasigma is a manufacturer and supplier of pharmaceutical products. The company offers prescription and over the counter drugs for the treatment of gastrointestinal disorders; drugs for diabetes and vascular diseases; nutraceuticals and medical foods. It also produces medicines to treat cardiology, orthopaedics, rheumatology, broncho-pneumology indications. Alfasigma is investigating drugs against gastroenterology, vascular disease and neuroscience disorders. The company operates a contract manufacturing office in Alanno, Pescara, Italy. It has operational presence in Belgium, China, Czech Republic, France, India, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovak Republic, Spain, Switzerland, Tunisia and the US. Alfasigma is headquartered in Bologna, Emilia-Romagna, Italy
For a complete picture of Rifaximin DR’s drug-specific PTSR and LoA scores, buy the report here.